Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 2, 2000, Pages 516-521

  Leviev, Ilia ^a   James, Richard W ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Atherosclerosis; Gene expression; HDL; Oxidative stress

Indexed keywords

ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN;

ADULT; AMINO ACID SEQUENCE; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; GENOTYPE; HUMAN; HUMAN CELL; MALE; OXIDATION; PRIORITY JOURNAL; PROMOTER REGION; PROTECTION; REPORTER GENE;

EID: 0033973018     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.2.516     Document Type: Article

References (28)

1. Blatter M-C, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45: identity of K-45 with paraoxonase. Eur J Biochem. 1993;211:871-879.
2. La Du BN. Human serum paraoxonase/arylesterase. In: Kalow W, ed. Pharmacogenetics of Drug Metabolism. New York, NY: Pergamon Press; 1992:51-91.
3. Mackness MI, Arrol S, Abbot C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129-135.
4. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96:2882-2891.
5. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parma SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest. 1998;101:1581-1590.
6. Shin DM, Gu L, Xia Y-R, Navab M, Li W-F, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284-287.
7. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. J Clin Invest. 1995;96:2758-2767.
8. Shin DM, Gu L, Hama S, Xia Y-R, Navab M, Fogelman AM, Lusis AJ. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest. 1996;97: 1630-1639.
9. Blatter Garin M-C, James RW, Dussoix P, Blanché H, Passa P, Froguel P, Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme: a possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest. 1997;99:62-66.
10. Leviev I, Negro F, James RW. Two alleles of the human paraoxonase gene produce different amounts of mRNA: an explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol. 1997;17: 3935-3939.
11. Blatter Garin M-C, Abbot C, Messmer S, Mackness MI, Durrington P, Pometta D, James RW. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J. 1994;304:549-554.
12. Kadonaga JT, Carner KR, Masiarz FR, Tjian R. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell. 1987;51:1079-1090.
13. Saikawa Y, Price K, Hance KW, Chen TY, Elwood PC. Structural and functional analysis of the human KB cell folate receptor gene P4 promoter: cooperation of 3 clustered Sp1-binding sites with the initiator region for basal promoter activity. Biochemistry. 1995;34:9951-9961.
14. Sun XM, Neuwirth C, Wade DP, Knight BL, Soutar AK. A mutation (T-45C) in the promoter region of the low density lipoprotein (LDL)-receptor gene is associated with mild clinical phenotype in a patient with heterozygous familial hypercholesterolaemia (FH). Hum Mol Genet. 1995;4:2125-2129.
15. Ruiz J, Blanché H, James RW, Blatter MC, Charpentier G, Morabia A, Passa P, Froguel P. The polymorphism (Gln-Arg192) of the high-density lipoprotein-bound enzyme paraoxonase is an independent cardiovascular risk factor in non-insulin dependent diabetic patients. Lancet. 1995;346:869-872.
16. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary heart disease. J Clin Invest. 1995;96:3005-3008.
17. 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol. 1997;17:3565-3569.
18. Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphisms of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol. 1997;17:1067-1073.
19. Odawara M, Tachi Y, Yamashita K. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetic patients. J Clin Endocrinol Metab. 1997; 82:2257-2260.
20. Pfohl M, Koch M, Enderle MD, Kühn R, Füllhase J, Karsch KR, Häring HU. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes. 1999;48:623-627.
21. Antikainen M, Murtomaki S, Syvänne M, Pahlman R, Tahvanainen E, Jauhiainen M, Frick MH, Ehnholm C. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with risk of coronary artery disease in Finns. J Clin Invest. 1996;98:883-885.
22. Herrmann S-M, Blanc H, Poirier O, Arveiler D, Luc G, Evans A, Marques-Vidal P, Bard J-M, Cambien F. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis. 1996;126:299-304.
23. Sakai T, Ohtani N, McGee TL, Robbins PD, Dryja TP. Oncogenic germ line mutations in Sp1 and ATF sites in the human retinoblastoma gene. Nature. 1991;353:83-86.
24. Koivisto UM, Palvimo JJ, Janne OA, Kontula K. A single base substitution in the proximal Sp1 site of the human low density lipoprotein receptor promoter as a cause of heterozygous familial hypercholesterolemia. Proc Natl Acad Sci U S A. 1994;91:10526-10530.
25. Brealey CJ, Walker CH, Baldwin BC. A-esterase activities in relation to the differential toxicity of pirimiphos-methyl to birds and mammals. Pestic Sci. 1980;11:546-554.
26. Li W-F, Costa CE, Furlong CE. Serum paraoxonase status: a major factor in determining resistance to organophosphates. J Toxicol Environ Health. 1993;40:337-346.
27. Playfer JR, Eze LC, Bullen MF, Evans DAP. Genetic polymorphisms and interethnic variability of plasma paraoxonase activity. J Med Genet. 1976;13:337-342.
28. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993;3:73-76.